Most Recent Articles by Bryant Furlow
Tumor cell lines derived from single cells and curated at different reference labs have quietly evolved in vitro, accumulating distinct genomic aberrations.
The development of BRCA-targeted therapies might offer the best opportunities to bring pancreatic cancer into the precision-oncology era.
A meta-analysis of 20 randomized clinical trials found that men may infer a greater benefit from immune checkpoint inhibition.
The IASLC released guidance on the use of biopsies for the detection of EGFR and other tumor mutations in patients with NSCLC.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
More Articles by Bryant Furlow
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA Status Could Inform Pancreatic Cancer Management
- Polypharmacy and Cancer
- Adoptive Cell Therapy in Solid Tumors Demonstrates Robust Antitumor Effects
- Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
- Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer